| 產(chǎn)品編號 | bs-10123R |
| 英文名稱 | IKK Alpha + IKK beta Rabbit pAb |
| 中文名稱 | KB抑制蛋白激酶α/β抗體 |
| 別 名 | IKK-alpha; I kappa A kinase 2; I kappa A kinase alpha; IkBKA; IKK 1; IKKA; IKK alpha; IKK A; IKK alpha; IKK1; IKKA; CHUK1; CHUK; IKK-β; I kappa B kinase 2; I kappa B kinase beta; IkBKB; IKK 2; IKKβ; IKK β; IKK B; IKK beta; IKK2; IKKB; Inhibitor of kappa light chain gene enhancer in B cells; Inhibitor of kappa light polypeptide gene enhancer in B cells; Inhibitor of kappa light polypeptide gene enhancer in B cells kinase beta; Inhibitor of nuclear factor kappa B kinase beta subunit; Inhibitor of nuclear factor kappa B kinase subunit beta; MGC131801; NFKBIKB; Nuclear factor NF kappa B inhibitor kinase beta; Nuclear factor of kappa light chain gene enhancer in B cells inhibitor; IKKA_HUMAN; IKKB_HUMAN. IKK α/IKK β; IKK-α/IKK-β; |
 |
Specific References (3) | bs-10123R has been referenced in 3 publications.
[IF=7.561] Qihong Zhang. et al. ACSL1 Inhibits ALV-J Replication by IFN-Ⅰ Signaling and PI3K/Akt Pathway. Front Immunol. 2021; 12: 774323 WB ; Chicken.
[IF=5.955] Weiqi Meng. et al. ZhenQi FuZheng formula inhibits the growth of colorectal tumors by modulating intestinal microflora-mediated immune function. AGING-US. 2022 Jun 15; 14(11): 4769–4785 WB ; Mouse.
[IF=5.037] Yuhua Li. et al. Study on the mechanism of Yupingfeng powder in the treatment of immunosuppression based on UPLC?QTOF?MS, network pharmacology and molecular biology verification. Life Sci. 2022 Jan;289:120211 WB ; Mouse.
|
| 研究領(lǐng)域 | 腫瘤 細(xì)胞生物 信號轉(zhuǎn)導(dǎo) 轉(zhuǎn)錄調(diào)節(jié)因子 激酶和磷酸酶 |
| 抗體來源 | Rabbit |
| 克隆類型 | Polyclonal |
| 交叉反應(yīng) | Human,Mouse (predicted: Rat,Pig,Cow,Chicken,Dog,Horse) |
| 產(chǎn)品應(yīng)用 | IHC-P=1:100-500,IHC-F=1:100-500,IF=1:100-500
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理論分子量 | 83 kDa |
| 檢測分子量 | |
| 細(xì)胞定位 | 細(xì)胞核 細(xì)胞漿 細(xì)胞膜 |
| 性 狀 | Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human IKK Alpha/IKK beta: 151-250/756 |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 緩 沖 液 | 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| 保存條件 | Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles. |
| 注意事項(xiàng) | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 產(chǎn)品介紹 |
IKK Alpha/IKK beta is a member of the IKK complex which is composed of IKK alpha, IKK beta, IKK gamma and IKAP. Phosphorylation of I-Kappa-B on a serine residue by the IKK complex frees NF-kB from I-Kappa-B and marks it for degradation via ubiquination. IKK beta has been shown to activate NF-kB and phosphorylate IKB alpha and beta. Phosphorylation of 2 sites at the activation loop of IKK beta is essential for activation of IKK by TNF and IL1. Once activated, IKK beta autophosphorylates which in turn decreases IKK activity and prevents prolonged activation of the inflammatory response. Additionally, IKK beta activity can also be regulated by MEKK1.
Subunit: Component of the I-kappa-B-kinase (IKK) core complex consisting of CHUK, IKBKB and IKBKG; probably four alpha/CHUK-beta/IKBKB dimers are associated with four gamma/IKBKG subunits. The IKK core complex seems to associate with regulatory or adapter proteins to form a IKK-signalosome holo-complex. The IKK complex associates with TERF2IP/RAP1, leading to promote IKK-mediated phosphorylation of RELA/p65. Part of a complex composed of NCOA2, NCOA3, CHUK/IKKA, IKBKB, IKBKG and CREBBP. Part of a 70-90 kDa complex at least consisting of CHUK/IKKA, IKBKB, NFKBIA, RELA, IKBKAP and MAP3K14. Found in a membrane raft complex, at least composed of BCL10, CARD11, DPP4 and IKBKB. Interacts with SQSTM1 through PRKCZ or PRKCI. Forms an NGF-induced complex with IKBKB, PRKCI and TRAF6. May interact with MAVS/IPS1. Interacts with NALP2. Interacts with TICAM1. Interacts with Yersinia yopJ. Interacts with FAF1; the interaction disrupts the IKK complex formation. Interacts with ATM. Part of a ternary complex consisting of TANK, IKBKB and IKBKG. Interacts with NIBP; the interaction is direct. Interacts with ARRB1 and ARRB2. Interacts with TRIM21. Interacts with NLRC5; prevents IKBKB phosphorylation and kina Subcellular Location: Cytoplasm. Nucleus. Membrane raft. Note=Colocalized with DPP4 in membrane rafts. Tissue Specificity: IKK beta: Highly expressed in heart, placenta, skeletal muscle, kidney, pancreas, spleen, thymus, prostate, testis and peripheral blood. IKK alpha: Widely expressed. Post-translational modifications: Phosphorylated by MAP3K14/NIK, AKT and to a lesser extent by MEKK1, and dephosphorylated by PP2A. Autophosphorylated. Acetylation of Thr-179 by Yersinia yopJ prevents phosphorylation and activation, thus blocking the I-kappa-B signaling pathway. DISEASE: Defects in CHUK are the cause of cocoon syndrome (COCOS) [MIM:613630]; also known as fetal encasement syndrome. COCOS is a lethal syndrome characterized by multiple fetal malformations including defective face and seemingly absent limbs, which are bound to the trunk and encased under the skin. Similarity: Belongs to the protein kinase superfamily. Ser/Thr protein kinase family. I-kappa-B kinase subfamily. Contains 1 protein kinase domain. SWISS: O15111 Gene ID: 1147 Database links: Entrez Gene: 1147 Human Entrez Gene: 3551 Human Entrez Gene: 12675 Mouse Entrez Gene: 16150 Mouse Omim: 600664 Human Omim: 603258 Human SwissProt: O14920 Human SwissProt: O15111 Human SwissProt: O88351 Mouse SwissProt: Q60680 Mouse Unigene: 198998 Human Unigene: 413513 Human |
| 產(chǎn)品圖片 |
Paraformaldehyde-fixed, paraffin embedded (human liver); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; An
Paraformaldehyde-fixed, paraffin embedded (Mouse brain); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; A
|
